Abstract Learning Objectives After completing this course, the reader will be able to:
Describe the mechanisms that result in resistance to imatinib in CML patients. Employ the …

Chronic myeloid leukemia (CML) is a progressive and often fatal myeloproliferative
neoplasm. The hallmark of CML is an acquired chromosomal translocation known as the …

Chronic myeloid leukemia (CML) is a progressive and often fatal malignancy of the blood.
The harbinger of CML is a chromosomal translocation that results in the synthesis of the …

Small molecule tyrosine kinase inhibitors (TKIs) are potent anti-cancer targeted therapies.
TKIs are considered safe and efficacious therapeutic modalities, and are generally tolerated …

Chronic myelogenous leukaemia (CML) is a progressive and often fatal haematopoietic
neoplasm. The Bcr-Abl tyrosine kinase inhibitor imatinib mesylate represented a major …

Imatinib mesylate is currently the drug of choice for all phases of chronic myeloid leukemia
(CML). Despite the initial high rates of hematological and cytogenetic responses, many …

Aims and objectives. To review the use of second‐line tyrosine kinase inhibitors in patients
with chronic myeloid leukaemia (CML) and provide recommendations for managing adverse …

The development of imatinib has revolutionized the treatment of chronic myeloid leukemia.
Follow-up analysis of IRIS trial participants continues to demonstrate durable responses for …

Imatinib (IM)-associated myelosuppression is rare in gastrointestinal stromal cell tumors (<
10%) but common in chronic myeloid leukemia (CML). Selective inhibition of predominantly …

Imatinib is widely recognized as the standard of care in the first-line treatment of chronic
myeloid leukemia (CML); however, resistance can limit its long-term benefits. Early …